Modality
Small Molecule
MOA
SGLT2i
Target
TYK2
Pathway
STING
T2DDLBCL
Development Pipeline
Preclinical
~Aug 2014
→ ~Nov 2015
Phase 1
~Feb 2016
→ ~May 2017
Phase 2
Aug 2017
→ Apr 2031
Phase 2Current
NCT07899776
1,101 pts·T2D
2017-08→TBD·Active
NCT04742728
1,874 pts·DLBCL
2023-07→2031-04·Recruiting
2,975 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-10-155mo agoConference· DLBCL
2031-04-135.0y awayPh3 Readout· DLBCL
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P2/3
Active
P2/3
Recruit…
Catalysts
Conference
2025-10-15 · 5mo ago
DLBCL
Ph3 Readout
2031-04-13 · 5.0y away
DLBCL
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07899776 | Phase 2/3 | T2D | Active | 1101 | PASI75 |
| NCT04742728 | Phase 2/3 | DLBCL | Recruiting | 1874 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Motazanubrutinib | Biogen | Preclinical | CD38 | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 | |
| COR-9566 | Corcept | Approved | TYK2 | |
| SND-9531 | Syndax | Phase 3 | TYK2 |